Literature DB >> 22826983

[Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].

Zoran Andrić, Tomislav Randjelović, Vladimir Kovčin, Jasmina Gutović, Slobodanka Crevar, Zafir Murtezani, Sanja Kostić.   

Abstract

INTRODUCTION: Still there is no consensus on the choice of the most efficient and the least toxic chemotherapy regimen in the treatment of advanced gastric cancer. Nowadays few therapy protocols are available for treating this disease.
OBJECTIVE: Study was conducted to compare the efficacy and toxicity of FAM (flurouracil, doxorubicin, mitomycin C) with CDDP and FU/FA (cisplatin, 5-fluorouracil, leucovorin) protocols in patients with locally advanced and metastatic gastric cancer.
METHODS: This randomized study involved a group of 50 patients with locally advanced or metastatic gastric cancer, who had not previously undergone chemotherapy treatment. Progression free survival, overall survival and drug toxicity were evaluated. For statistical analysis chi-squaretest, Kaplan-Meier curve and the log rank test were used.
RESULTS: The overall response rate was 20% in the group treated with FAM and 24% in the group treated with CDDP, FU/FA (4% of patients from each group had complete response), but without significant statistical difference. Median survival was 10.9 months in the FAM group and 11.8 months in CDDP, FU/FA group, with no statistically significant difference. Non-haematological and haematological toxicities of CDDP, FU/FA were considerably less frequent than of FAM, and there was no treatment related deaths in any of the groups.
CONCLUSION: Both investigated regimens demonstrated moderate efficacy. The study shows in favour of justified application of both protocols, while in regard to toxicity CDDP and FU/FA can be recommended as preferable treatment for locally advanced and metastatic gastric cancer. New strategies should be considered for better efficacy in the treatment of advanced gastric cancer. New strategies are necessary with the goal to achieve a better therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826983     DOI: 10.2298/sarh1206305a

Source DB:  PubMed          Journal:  Srp Arh Celok Lek        ISSN: 0370-8179            Impact factor:   0.207


  3 in total

1.  Methodological Errors in Clinical Studies Published by Medical Journals of Ex-Yugoslav Countries.

Authors:  Slobodan M Jankovic; Izet Masic
Journal:  Acta Inform Med       Date:  2020-06

Review 2.  Chemotherapy for advanced gastric cancer.

Authors:  Anna Dorothea Wagner; Nicholas Lx Syn; Markus Moehler; Wilfried Grothe; Wei Peng Yong; Bee-Choo Tai; Jingshan Ho; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

3.  Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.

Authors:  Lin Wang; Pei-Feng Li; Ming Geng; Yong-Cheng Cao; Ying-Chun Yin
Journal:  Diagn Pathol       Date:  2013-02-22       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.